A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the vaccine safeguards at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by activating the mother’s immune system to generate protective antibodies, which are then passed to the developing baby through the placenta. This mother-derived protection provides newborns with instant defence from the point of delivery, precisely when they are highly susceptible to RSV. The new study shows that protection reaches approximately 85% when the vaccine is administered at least four weeks before delivery. Even briefer gaps between vaccination and birth can still deliver meaningful protection, with evidence indicating that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to receive the vaccine at the recommended time, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent coverage when immunised 4 weeks before birth
- Antibodies from the mother transferred through placenta protect newborns from day one
- Coverage possible with two-week gap before premature birth
- Vaccination during the third trimester still provides meaningful protection for infants
Compelling evidence from recent research
The effectiveness of the RSV vaccine administered during pregnancy has been demonstrated through a thorough investigation undertaken in England, reviewing data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately 90% of all births during that half-year window, providing comprehensive and reliable evidence of the vaccine’s actual performance. The study’s findings have been validated by the UK Health Security Agency as showing robust protection for newborns during their most critical early weeks. The scale of this research gives healthcare professionals and expectant parents with assurance in the vaccine’s proven efficacy across different groups and contexts.
The results present a notable picture of the vaccine’s protective power. More than 4,500 babies were hospitalised with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not been given the vaccination. This clear distinction highlights the vaccine’s vital importance in reducing the risk of serious illness in newborns. The reduction in hospital admissions surpassing 80 per cent represents a substantial public health milestone, helping to prevent thousands of infants from experiencing the alarming and potentially severe symptoms linked to severe RSV infection. These findings support the importance of the vaccination programme introduced in the UK in 2024.
Study methodology and scope
The research analysed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine clear comparisons of RSV infection rates and hospital admissions. The sizeable sample and comprehensive nature of the data collection ensured that findings were statistically robust and reflective of the wider population, rather than individual cases or small subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to determine the shortest interval needed between vaccination and birth for best possible protection, as well as to determine whether protection stayed significant with briefer timeframes. The methodology captured actual clinical results rather than laboratory-based settings, providing tangible evidence of how the vaccine functions when delivered across varied healthcare environments and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and its dangers
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity changing substantially from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.
The infection produces inflammation deep within the lungs and airways, making it dangerously difficult for vulnerable newborns to breathe and feed effectively. Parents commonly see their babies fighting for breath, their chests heaving as they work to get enough air into their damaged lungs. Whilst most newborns get better with clinical support, a small but significant number die from RSV-related complications yearly, making vaccination as prevention a essential public health imperative for defending the most vulnerable and youngest individuals in the population.
- RSV causes inflammation in lungs, leading to severe breathing difficulties in babies
- Half of all infants catch the infection in their first few months of life
- Symptoms span from mild colds to serious chest infections that threaten life needing hospital treatment
- More than 20,000 UK infants need serious hospital treatment for RSV annually
- Few infants succumb to RSV complications annually in the UK
Adoption rates and expert recommendations
Since the RSV vaccine programme began in 2024, health officials have stressed the significance of pregnant women receiving their jab at the best time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has stressed that the timing is essential for guaranteeing newborns receive the maximum immunity from birth. Whilst the research shows that vaccination performed at least four weeks prior to delivery provides approximately 85% protection, experts recommend women to get their vaccine as early as possible from 28 weeks of pregnancy onwards to increase the antibodies transferred to their babies through the placenta.
The guidance from public health bodies remains clear: pregnant women should make a priority of getting vaccinated during their final three months, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has provided reassurance to expectant mothers that protection is still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This flexible approach recognises the practical demands of pregnancy whilst maintaining strong safeguarding for at-risk infants during their earliest and most vulnerable period when RSV poses the greatest risk of severe infection.
Regional disparities in vaccination
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Some areas have attained greater immunisation rates among eligible pregnant women, whilst others continue working to boost understanding and access to the jab. These geographical variations demonstrate differences across healthcare infrastructure, communication strategies, and local engagement efforts, though the overall statistics demonstrates consistently strong protection irrespective of geographical location.
- NHS trusts deploying varied communication campaigns to reach women during pregnancy
- Inconsistencies across regions in immunisation take-up in different parts of England demand focused enhancement
- Local healthcare systems tailoring initiatives to meet specific population needs
Real-world impact and parental perspectives
The vaccine’s outstanding effectiveness provides tangible benefits for families across the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV prior to the rollout of this protective measure, the 80% drop in admissions means thousands of infants spared from critical disease. Parents no longer face the distressing scenario of watching their newborns gasping for air or difficulty feeding, symptoms that define serious RSV disease. The vaccine has markedly changed the landscape of neonatal breathing health, providing expectant mothers a preventative option to shield their most at-risk babies during those crucial first weeks.
For families like that of Malachi, whose serious RSV infection resulted in devastating brain damage, the vaccine’s availability carries significant emotional significance. His mother’s promotion of the jab underscores the life-altering consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such serious complications—hospital stay, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to pregnant women during their third trimester, changing what was once an inevitable seasonal threat into a manageable risk.